|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 18.69 USD | +5.65% |
|
+3.89% | -14.03% |
| 14/04 | Genscript Biotech Associate Logs $597 Million in Q1 Sales of Carvykti | MT |
| 12/03 | Legend Biotech Shares Likely to Rebound in 2026 on Robust Fundamentals, RBC Says | MT |
Company Valuation: Legend Biotech Corporation
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 7,175 | 8,357 | 10,938 | 5,969 | 4,015 | 3,457 | - | - |
| Change | - | 16.46% | 30.89% | -45.43% | -32.74% | -13.91% | - | - |
| Enterprise Value (EV) 1 | 6,446 | 7,855 | 9,959 | 4,496 | 3,480 | 2,610 | 2,322 | 1,854 |
| Change | - | 21.86% | 26.78% | -54.85% | -22.6% | -25.01% | -11.03% | -20.15% |
| P/E ratio | -17x | -17.8x | -20.5x | -33.9x | -13.4x | 301x | 18.7x | 13.9x |
| PBR | 15.3x | - | 8.75x | 5.74x | 4.01x | 3.22x | 2.54x | 1.89x |
| PEG | - | -8.13x | -4.1x | 0.5x | -0.2x | -3x | 0x | 0.4x |
| Capitalization / Revenue | 79.9x | 71.4x | 38.4x | 9.52x | 3.9x | 2.41x | 1.89x | 1.63x |
| EV / Revenue | 71.8x | 67.1x | 34.9x | 7.17x | 3.38x | 1.82x | 1.27x | 0.87x |
| EV / EBITDA | -17.9x | -17.7x | -25.4x | -39.7x | -15x | 20.8x | 6.21x | 3.09x |
| EV / EBIT | -17.3x | -17.2x | -24.1x | -32.9x | -13.3x | 35.2x | 6.39x | 3.36x |
| EV / FCF | -26.6x | -33.1x | -24.1x | -28.4x | -27x | 19.4x | 5.57x | 2.93x |
| FCF Yield | -3.76% | -3.02% | -4.15% | -3.52% | -3.7% | 5.15% | 17.9% | 34.2% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -2.74 | -2.8 | -2.94 | -0.96 | -1.62 | 0.062 | 0.9975 | 1.343 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 89.79 | 117 | 285.1 | 627.2 | 1,029 | 1,436 | 1,831 | 2,121 |
| EBITDA 1 | -360.6 | -443.2 | -392.1 | -113.2 | -232.2 | 125.2 | 373.6 | 599.1 |
| EBIT 1 | -373 | -455.8 | -412.6 | -136.5 | -261.2 | 74.05 | 363.6 | 552.3 |
| Net income 1 | -386.2 | -446.3 | -518.3 | -177 | -296.8 | 67.01 | 320.2 | 501.1 |
| Net Debt 1 | -729.5 | -501.5 | -979.4 | -1,473 | -534.9 | -846.9 | -1,135 | -1,603 |
| Reference price 2 | 46.61 | 49.92 | 60.17 | 32.54 | 21.74 | 18.69 | 18.69 | 18.69 |
| Nbr of stocks (in thousands) | 153,946 | 167,403 | 181,789 | 183,451 | 184,690 | 184,943 | - | - |
| Announcement Date | 18/3/22 | 30/3/23 | 11/3/24 | 11/3/25 | 10/3/26 | - | - | - |
1USD in Million2USD
Estimates
P/E ratio, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 285.32x | 1.69x | 19.52x | -.--% | 3.27B | |
| 27.75x | 7.34x | 21.87x | 0.05% | 49.28B | |
| 18.15x | 5.47x | 12.43x | 1.63% | 46.64B | |
| -58.3x | 18.85x | -63.74x | -.--% | 32.62B | |
| -18.44x | 4.15x | -8.2x | -.--% | 24.45B | |
| 28.05x | 5.48x | 15.24x | -.--% | 18.64B | |
| 23.17x | 4.05x | 12.38x | -.--% | 17.27B | |
| -392.22x | 32.75x | 1803.08x | -.--% | 16.21B | |
| -16.08x | 1793.25x | -22.42x | -.--% | 15.53B | |
| -203.55x | 49.51x | -196.64x | -.--% | 14.5B | |
| Average | -30.61x | 192.25x | 159.35x | 0.17% | 23.84B | |
| Weighted average by Cap. | -32.89x | 128.39x | 108.88x | 0.33% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Equities
- LEGN Stock
- Valuation Legend Biotech Corporation
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition